. 2021 Oct 1;29(1):339–344. doi: 10.1111/ene.15113

TABLE 1.

Characteristics of cerebral venous sinus thrombosis (CVST) cases with thrombocytopenia within 28 days after adenoviral vector SARS‐CoV‐2 vaccination

	Patients with CVST after adenoviral vector vaccination N = 266
	Until 28 March N = 99	After 28 March N = 167
Age, median (IQR), years	46 (33–57)^†	46 (37–55)^‡
Female sex, n/N (%)	83/99 (84)	108/167 (65)
Intracranial haemorrhage at baseline, n/N (%) ^a	28/79 (35)	43/144 (30)
Confirmed COVID‐19 infection, n/N (%) ^b	1/99 (1)	2/167 (1)
Lowest reported platelet count, median (IQR), ×10⁹/L	27 (14–60)^††	42 (20–65)^‡‡
Mortality, n/N (%)	47/99 (47) ^c	36/167 (22) ^c

Number of missing values: ^†18; ^‡29; ^††17; ^‡‡46.

Abbreviations: COVID‐19, coronavirus disease 2019; CVST, cerebral venous sinus thrombosis; IQR, interquartile range.

^{^a}

Missing cases (N = 43) had an intracranial haemorrhage with an unknown onset date.

^{^b}

One patient had a COVID‐19 infection prior to CVST onset; the date of COVID‐19 infection onset was unknown in the other two patients.

^{^c}

p < 0.001.